Forum Posts

Md Shafikul Islam
Jul 17, 2022
In Welcome to the Forum
Today they represent 15% of the world drug market, more than Country Email List 600,000 million dollars, and it is expected that they will reach 25% in the next ten years, especially due to the expiration of patents. In 2009 Sigman created mAbxience, a division of Chemo specializing Country Email List in monoclonal antibodies, or mAbs, biosimilars used to neutralize foreign objects such as tumors. In 2012 he inaugurated the pilot plant in Munro, an old semi-abandoned industrial hub in the north of the province of Buenos Aires. The company soon made agreements with laboratories in Russia, Iran, Country Email List Turkey, and Southeast Asia. Sigman's biotechnological adventures in. America know two milestones. The first is the development of a vaccine Country Email List to treat lung cancer. A project that Sigman began in the mid-1990s in Cuba, with the development of the NgcCM3 antigen, and culminated in 2013 with the presentation of Racotumomab , t Country Email List he first vaccine that makes lung cancer chronic, transforming a deadly disease into a treatable disease such as diabetes or hypertension. The 18 years of research and development involved Sigman's companies, national universities, Cuban and Argentine research centers (including the National Council for Scientific and Technical Research Country Email List of Argentina) and the support of two ministries. The second milestone was the creation of Sinergium Biotech. During the 2009 H1N1 flu pandemic. Sigman proposed to the Argentine government, through the then Minister Country Email List of Health Juan Manzur, a pharmaceutical technology transfer project in exchange for the granting of a provisional monopoly, inspired by a similar project of the Brazilian government. Country Email List The tender was presented favoring Sigman as "author of the initiative", with the commitment to acquire all the vaccines produced. The agreement was made with the multinational Novartis, V Country Email List which would have a three-year monopoly on the flu vaccine, while transferring the technology to Elea and Biogenesis Bagó, through a company created for this purpose: Sinergium Biotech. After three years, Sinergium would be the exclusive manufacturer. In 2012, the World.
October And Country Email List content media
0
0
4
 

Md Shafikul Islam

More actions